Brief: Inozyme Pharma Reports First Quarter 2023 Financial Results And Provides Business Highlights
Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND
PROVIDES BUSINESS HIGHLIGHTS
* CURRENT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
ANTICIPATED TO FUND CASH FLOW REQUIREMENTS INTO Q4 OF 2024
* QTRLY NET LOSS PER SHARE $0.40
* Q1 EARNINGS PER SHARE VIEW $-0.45 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX39zXtp
Further company coverage: INZY.O
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin